Company intelligence / Profile preview
Cord for Life
- Ownership
- Private
- Development stage
- Commercial
Overview
Cord for Life has over three decades of experience as a leader in private and public umbilical cord blood banking. The company has participated in over 2,200 transplants using stored units. It offers both private storage and public donation options nationwide. Its proprietary technologies focus on maximizing viable stem cell recovery and ensuring high safety standards. The company recently announced a Phase I clinical trial to evaluate its PREMIERMAXCB® product—a biologic derived from umbilical cord blood—for treating lower back pain due to sacroiliac joint dysfunction; early research shows promising results but no published clinical outcomes yet.
- Therapeutic areas
- OtherRheumatologyHematology
- Modalities
- Stem cells (umbilical cord blood and tissue)cellular therapies
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cord for Life.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cord for Life.